Current and New Drugs for COVID-19 Treatment and Its Effects on the Liver
Open Access
- 19 April 2021
- journal article
- review article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000), 000
- https://doi.org/10.14218/jcth.2020.00174
Abstract
Corona virus disease (COVID)-19 is caused by the novel severe acute respiratory syndrome coronavirus-2 (commonly referred to as SARS-CoV-2). In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. Though the target organ for the virus is primarily the lungs, with the recent understanding of the pathobiology of this disease and the immune dysregulation associated with it, it is now clear that COVID-19 affects multiple organ systems. Several drugs and therapies have been tried or repurposed to combat the wrath posed by this disease. On October 22, 2020, the USA Food and Drug Administration approved remdesivir for use in adults and pediatric patients (12 years of age and older). Several of the drugs being tried against COVID-19 have hepatotoxicity as their potential side effect. This review aims to provide the latest insights on various drugs being used in the treatment of COVID-19 and their effects on the liver.Keywords
This publication has 99 references indexed in Scilit:
- Anakinra-Induced Acute Liver Failure in an Adolescent Patient with Still's DiseasePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2016
- Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cellsEuropean Respiratory Journal, 2014
- A Case of Prolonged Cholestatic Hepatitis Induced by Azithromycin in a Young WomanCase Reports in Hepatology, 2011
- Vanishing Bile Duct Syndrome Associated with Azithromycin in a 62‐Year‐Old ManBasic & Clinical Pharmacology & Toxicology, 2009
- First case of ivermectin-induced severe hepatitisTransactions of the Royal Society of Tropical Medicine and Hygiene, 2006
- Lopinavir/Ritonavir Induces the Hepatic Activity of Cytochrome P450 Enzymes CYP2C9, CYP2C19, and CYP1A2 But Inhibits the Hepatic and Intestinal Activity of CYP3A as Measured by a Phenotyping Drug Cocktail in Healthy VolunteersJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Severe acute hepatitis related to hydroxychloroquine in a woman with mixed connective tissue diseaseClinical Rheumatology, 2006
- Stevens-Johnson syndrome as an unusual adverse effect of azithromycin.2006
- Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patientsJournal of Antimicrobial Chemotherapy, 2005
- HIV Infection, Hepatitis C Infection, and HAARTJAMA, 2004